A citation-based method for searching scientific literature

Raymond R Townsend, Israel Machin, Jimmy Ren, Angelina Trujillo, Masato Kawaguchi, Ujjwala Vijapurkar, Chandrasekharrao V Damaraju, Michael Pfeifer. J Clin Hypertens (Greenwich) 2016
Times Cited: 57



H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
Times Cited: 410




List of shared articles



Times cited

SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature.
Konstantinos Imprialos, Charles Faselis, Chrysoula Boutari, Konstantinos Stavropoulos, Vasilios Athyros, Asterios Karagiannis, Michael Doumas. Curr Pharm Des 2017
10

Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease.
Kazuomi Kario, Keith C Ferdinand, James H O'Keefe. Prog Cardiovasc Dis 2020
12


The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action.
Eirini Lioudaki, Emmanouil S Androulakis, Martin Whyte, Konstantinos G Stylianou, Eugenios K Daphnis, Emmanouil S Ganotakis. Cardiovasc Drugs Ther 2017
6

Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?
Konstantinos P Imprialos, Chrysoula Boutari, Konstantinos Stavropoulos, Michael Doumas, Asterios I Karagiannis. J Neurol Neurosurg Psychiatry 2017
25





Lowering Blood Pressure with the Combination of a Sodium-Glucose Cotransporter 2 Inhibitor and a Glucagon-like Peptide-1 Receptor Agonist in Type 2 Diabetic Patients: A Clinical Evidence.
José Carlos Arévalo-Lorido, Juana Carretero Gómez, Ricardo Gómez Huelgas, Dolores García de Lucas, Lourdes Mateos Polo, José Manuel Varela Aguilar, Javier Ena Muñoz. High Blood Press Cardiovasc Prev 2018
1


Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial.
Aris Liakos, Vaia Lambadiari, Alexandra Bargiota, Konstantinos Kitsios, Iakovos Avramidis, Kalliopi Kotsa, Spyridon Gerou, Panagiota Boura, Nikolaos Tentolouris, George Dimitriadis,[...]. Diabetes Obes Metab 2019
13

Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension.
Ilkka Tikkanen, Robert Chilton, Odd Erik Johansen. Curr Opin Nephrol Hypertens 2016
26

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis.
William L Baker, Leo F Buckley, Michael S Kelly, John D Bucheit, Eric D Parod, Roy Brown, Salvatore Carbone, Antonio Abbate, Dave L Dixon. J Am Heart Assoc 2017
73


The effect of SGLT2 inhibitors on cardiovascular events and renal function.
Konstantinos P Imprialos, Konstantinos Stavropoulos, Michael Doumas, Asterios Karagiannis, Vasilios G Athyros. Expert Rev Clin Pharmacol 2017
7


Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure.
Konstantinos Imprialos, Konstantinos Stavropoulos, Vasilios Papademetriou. Heart Fail Clin 2019
0


Medical management of resistant hypertension: the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i).
Muhannad Alqudsi, Juan Carlos Q Velez, Jose Navarrete. Curr Opin Cardiol 2021
0

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.
Tricia Santos Cavaiola, Jeremy Pettus. Diabetes Metab Syndr Obes 2018
12

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
Jennifer R Donnan, Catherine A Grandy, Eugene Chibrikov, Carlo A Marra, Kris Aubrey-Bassler, Karissa Johnston, Michelle Swab, Jenna Hache, Daniel Curnew, Hai Nguyen,[...]. BMJ Open 2019
60


The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection.
Charalampos Loutradis, Eirini Papadopoulou, Marietta Theodorakopoulou, Asterios Karagiannis, Pantelis Sarafidis. Future Med Chem 2019
13

An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.
Joseph A Messana, Stanley S Schwartz, Raymond R Townsend. Vasc Health Risk Manag 2017
5

The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia.
Charalampos Loutradis, Eirini Papadopoulou, Elena Angeloudi, Asterios Karagiannis, Pantelis Sarafidis. Curr Med Chem 2020
11